Literature DB >> 1406898

In vitro activity of cloconazole, sulconazole, butoconazole, isoconazole, fenticonazole, and five other antifungal agents against clinical isolates of Candida albicans and Candida spp.

J M Hernández Molina1, J Llosá, A Martinez Brocal, A Ventosa.   

Abstract

The in vitro activity of several new imidazoles, cloconazole, sulconazole, butoconazole, isoconazole and fenticonazole, were compared with those of amphothericin B, flucytosine, and three azoles: econazole, miconazole and ketoconazole against isolates of pathogenic Candida. A total of 186 clinical isolates of 10 species of the genus Candida and two culture collection strains were tested by an agar-dilution technique. Isoconazole was the most active azole, followed by butoconazole sulconazole. Differences between some of the species in their susceptibility to the antifungal agents were noted. Sulconazole and cloconazole had the highest activity in vitro against 106 isolates of C. albicans. Butoconazole and isoconazole were also very active against isolates of C. albicans, and were the most active azole compounds against 80 isolates of Candida spp.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1406898     DOI: 10.1007/bf00472565

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  22 in total

1.  Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii.

Authors:  J D Dick; B R Rosengard; W G Merz; R K Stuart; G M Hutchins; R Saral
Journal:  Ann Intern Med       Date:  1985-01       Impact factor: 25.391

2.  In-vitro resistance to imidazole antifungals in Candida albicans.

Authors:  E M Johnson; M D Richardson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

3.  Decreased activity of UMP pyrophosphorylase associated with resistance to 5-fluorocytosine in Candida albicans.

Authors:  W L Whelan; D Kerridge
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

4.  New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice.

Authors:  E Lefler; D A Stevens
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

5.  Intravenous catheter-associated fungemia due to Candida rugosa.

Authors:  J F Reinhardt; P J Ruane; L J Walker; W L George
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

6.  Laboratory methods for flucytosine (5-fluorocytosine). Report of a Working Group of the British Society for Mycopathology.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1984-07       Impact factor: 5.790

7.  Ultrastructure of Candida parapsilosis endocarditis.

Authors:  T J Marrie; J H Cooper; J W Costerton
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

8.  Disseminated Candida infection syndrome in heroin addicts--dominance of a single Candida albicans biotype.

Authors:  F C Odds; A Palacio-Hernanz; J Cuadra; J Sanchéz
Journal:  J Med Microbiol       Date:  1987-05       Impact factor: 2.472

9.  Susceptibility of clinical isolates of yeasts to anti-fungal agents.

Authors:  S M Hussain Qadri; D J Flournoy; S G Qadri; E G Ramirez
Journal:  Mycopathologia       Date:  1986-09       Impact factor: 2.574

10.  Incidence of polyene-resistant yeasts recovered from clinical specimens.

Authors:  J D Dick; W G Merz; R Saral
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

View more
  3 in total

Review 1.  Caenorhabditis elegans-based model systems for antifungal drug discovery.

Authors:  Cleo G Anastassopoulou; Beth Burgwyn Fuchs; Eleftherios Mylonakis
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 2.  Conazoles.

Authors:  Jan Heeres; Lieven Meerpoel; Paul Lewi
Journal:  Molecules       Date:  2010-06-09       Impact factor: 4.411

3.  Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay.

Authors:  Ikechukwu Okoli; Jeffrey J Coleman; Emmanouil Tampakakis; Emmanouil Tempakakis; W Frank An; Edward Holson; Florence Wagner; Annie L Conery; Jonah Larkins-Ford; Gang Wu; Andy Stern; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.